The Zyduses vaccine, as originally developed by Biohaven Pharmaceuticals, is based on a virus engineered to contain a protein that is essential for life.
Biohaven has been working to develop and commercialize the vaccine in collaboration with other labs, and its preliminary results have been impressive.
The new version of the vaccine, which was approved for use in humans in May, has a much smaller dose, a higher level of safety and a lower risk of side effects.
But while the vaccine is expected to reduce vaccine-preventable deaths by roughly 40 percent, the new version also has a slightly higher rate of side-effects, which is a concern for some doctors who have used the Zyvs to treat multiple sclerosis patients.
“There are still questions,” said David DeFilippis, the vice president of medical affairs at the American Academy of Neurology.
“Is this vaccine safe?
Is it going to be effective?
And if it is, how does it affect other people?
And do we know what it’s going to do to us?”
As we reported last month, Biohaven’s preliminary findings, published in JAMA Neurology, showed that the vaccine reduces the risk of a variety of serious side effects by a staggering 50 percent, including dizziness, confusion, fatigue, diarrhea, and nausea.
However, the results are far from definitive.
“The big question is: How do you reduce that risk of serious outcomes?”
DeFillardis told Ars.
“Because, I think, we don’t know enough about the vaccine to be confident that we’re going to make the vaccine safe.”
To address those concerns, BioHawkins researchers are now working on further testing.
They are working on testing the vaccine against a new variant of the coronavirus, a strain that has not yet been isolated.
“We’ve got a very promising variant of coronaviruses that we haven’t seen in the wild,” DeFillonis said.
“And so, we’re working on some very novel testing.”
If the vaccine proves effective, it would likely be used to treat the disease for which it was developed, although some researchers have suggested that this is a relatively unlikely scenario.
That is, of course, if the vaccine’s efficacy is even remotely comparable to what has been seen in clinical trials of the original version. “
But, you know, this is the first vaccine that’s been developed and tested against a coronaviral variant, and we haven.t seen anything.”
That is, of course, if the vaccine’s efficacy is even remotely comparable to what has been seen in clinical trials of the original version.
If the new vaccine proves to be even more effective, DeHollis added, “I would be shocked if it wasn’t.”
The main obstacle to the Zyguses vaccine being approved for human use is the fact that the FDA doesn’t allow the use of the virus in humans.
That is partly because it’s considered an unapproved experimental treatment for certain kinds of brain cancers.
The other major hurdle is that the American Heart Association has said that the Zyx vaccine poses a danger to people who have already been diagnosed with brain tumors.
“That’s where we have some hesitancy, because if you take a Zydusk, you have a brain tumor,” DeHillardis said, referring to the original Zydens.
“It could be that there’s some sort of residual infection or whatever.”
The FDA hasn’t yet made any statements on whether the vaccine might be unsafe.
DeFollis told us that it is possible that the agency could reconsider its decision, but he added that “we are not there yet.”
For now, however, he said that “the company is really focused on this vaccine and is very confident that it’s gonna work.”